Category Archives: Epigenetics

Fort Collins, Colorado Reports Globe recently published a report on the Epigenetics Market. The study was supported by data obtained either from primary sources or from corporate databases. The experts in the market have confirmed that the data is realistic and relevant to the particular market conditions and therefore will prove extremely helpful to the user. The factors that have been broken down into driver and restraint systems. The regions, types, applications, and strategies are segmented and subdivided for better and better understanding.

This report covers the current economic impact of COVID-19. This outbreak drastically changed the global economic situation. The current scenario of the constantly evolving corporate sector, as well as the present and future assessment of the impact, are also addressed in the report.

Epigenetics market garnered a revenue of USD 7.4 billion in the year 2019 globally and has been foreseen to yield USD 30.1 billion by the year 2027 at a compound annual growth (CAGR) of 18.9% over the forecast period.

The Epigenetics marketreport gives a 360 approach for a holistic understanding of the market scenario. It relies on authentically-sourced information and an industry-wide analysis to predict the future growth of the sector. The study gives a comprehensive assessment of the Epigenetics industry, along with market segmentation, product types, applications, and value chain.

Leading Epigenetics manufacturers/companies operating at both regional and global levels:

F. Hoffmann-La Roche Ltd

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Research Objective:

Our panel of trade analysts has taken immense efforts in doing this group action in order to produce relevant and reliable primary & secondary data regarding the Epigenetics market. Also, the report delivers inputs from the trade consultants that will help the key players in saving their time from the internal analysis. Readers of this report are going to be profited with the inferences delivered in the report. The report gives an in-depth and extensive analysis of the Epigenetics market.

The Epigenetics Market is Segmented:

Epigenetics Market, By Technology (2016-2027)

Epigenetics Market, By Application (2016-2027)

Epigenetics Market, By Product (2016-2027)

This Epigenetics report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Epigenetics Market Regional Analysis:

Key Coverage of Report:

Key insights of the report:

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

View post:
Epigenetics Market Size and Growth 2020-2027 | Major Players Qiagen, Novartis AG, Active Motif, Merck Sharp & Dohme Corp, Thermo Fisher...

]]]]]] Volitions CEO, Cameron Reynolds spoke to Medical Technology about the companys story so far and what sets their technology apart from others in development. Credit: Volition

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.

Epigenetics company Volition is hoping to carve new ground in the cancer diagnostics space. Through measuring tumour nucleosomes (a type of epigenetic structure) in the blood, it is creating a range of blood tests that can detect cancer from the earliest stages. The company says these tests will be simple, cost-effective and easy to use.

With clinical trials underway, the company is now focused on bringing its toolbox of diagnostic products to market. Volitions CEO, Cameron Reynolds spoke to Medical Technology about the companys story so far and what sets their technology apart from others in development.

Abi Millar (AM): Whats the story behind Volition? Can you tell me a bit about your path to getting where you are today?

Cameron Reynolds (CR): We started ago nearly ten years ago, in September 2010. Were still using the same technology platform as we were then a lot of companies chop and change, but weve always believed in epigenetics and see them as really important in cancer diagnosis.

We started with one original patent application, which was licensed to us from Chroma Therapeutics. We wanted to commercialise this basic concept of using nucleosomes (a type of epigenetic structure) for a marker for cancer detection, and eventually a number of other diseases as well. So we set up a subsidiary in Belgium, which we felt was a good value place to develop research, and raised just over a million euros. We also have offices in Texas, London and Singapore.

Our whole ethos has been to make low-cost, routine cancer diagnostics with an ELISA based format. The ELISA platform is 35 years old our chief scientific officer Jake Micallef has been working on this format his entire life, and hes a big believer in keeping it affordable.

We started with our original patent, which was histone modifications, and then we patented everything else we did along the way, so we have very strong intellectual property. We began with diagnostics for human cancers, starting with colorectal, and then adding in lung cancer and some other cancers where weve had some good results.

Around two and a half years ago, we expanded the staff and moved into a bigger facility in Belgium. We now have 35 people working there, attempting to create a robust, reliable stable platform to measure the tumour nucleosomes in circulation. We went public in 2015 on the New York Stock Exchange, since the capital markets are quite a good source of funding if you have something new and innovative.

Since then weve just been swimming in our own lane, developing our technology. Were in the process of launching a range of products over the next few years, and hopefully we can really do a good job with it.

AM: You are developing a range of blood tests for cancer diagnostics called Nu.Q, which has been described as an epigenetic toolbox. What is Nu.Q exactly? How does it work?

CR: We have several different ways of analysing the nucleosomes, ranging from a very simple microtitre plate-based ELISA format to a magnetic bead-based ELISA format. The new process were developing now, called Nu.Q Capture, involves capturing the nucleosomes on the machine, isolating them from the plasma, and conducting mass spectrometry analysis. This enables a greater concentration of nucleosomes.

Were using Nu.Q for our own purposes in cancer trials and other trials, and have also partnered with Texas A&M Veterinary School to find out whether our basic format could be useful in veterinary science too. Thats why we call Nu.Q a complete toolbox. Its a very robust reliable platform that can be used in all these different areas, and its a whole new way of analysing the epigenetic structures.

AM: What is different about this method, compared to other diagnostic assays for cancer?

CR: Since we started, there have been a lot of different cancer diagnostics in development, based on circulating tumour cells, DNA, exosomes, etcetera. But were still the only group ever to have looked at nucleosomes in circulation as a diagnostic.

We also have the ethos to keep it very affordable and easy to use. With a lot of companies its a complicated, expensive technology circulating DNA for instance requires a very large blood draw and quite expensive processes. Weve kept it simple, and we can do that because the markers were after are common in the blood and you can measure them with a simple ELISA format.

So theres always space for lots of different methods, but we think theres a very strong need for a low cost, reproducible reliable test that can be taken by huge numbers of people around the world as part of their normal medical work. That makes us unique not only in terms of the markers were after the nucleosomes but also in terms of the basic ethos. Weve spent the last two and half years fully optimising the platform itself so it can be robust, reproducible and reliable and accessible to any lab in the world.

AM: You currently have a number of clinical trials underway and presented some initial data at the 2020 ASCO Annual Meeting. What might the path to the clinic look like?

CR: We now have some markers that have shown very good efficacy in a range of cancers, but were also looking for differential markers between the different cancers. Were running some smaller trials for lung, colorectal and blood cancers some of the data was released at ASCO and now were putting together panels of those to get enough accuracy for a frontline test.

We also have some larger trials, like the early detection research network in the US, which will involve around 7,000-8,000 people. There are also some in Taiwan for lung and colorectal cancers, which will involve around 8,000-9,000 altogether.

So, weve got small and medium-sized trials along with some very large product trials. Thats on top of the trials we have in the veterinary space, as well as trials for things like Nu.Q Capture. Weve also had some very encouraging data in Covid-19, where were looking at prognostic outcomes.

Our assays are very low cost and easy to run with small amounts of blood, so we can run them in lots of different areas. There should be a lot of results coming through this year, next year and into 2022.

AM: What are your hopes for the future? What could the implications of your technology be further down the line?

CR: My hope is that our kits will enable much earlier diagnosis. That would really help to lower costs both in human terms and financially. If you get diagnosed early, you can survive it a lot longer of those diagnosed in stage 1, about 95% survive five years or more whereas its exactly the opposite if the cancer is found in stage 4. Thats obviously horrible for yourself and your family but its also a financial burden for health systems.

So hopefully it will have a very strong human impact on limiting the severity of the disease, as well as saving health systems and individuals money. This will make it affordable for healthcare systems in the developed and developing world, so we can hopefully save lives worldwide. And what we hope is that in five years, a large percentage of the worlds population who are either of age or at risk take our blood tests through routine blood work and we can do a lot of good in a lot of different areas.

AM: More generally, what do you expect the future of blood testing for cancer to look like?

CR: I certainly hope the other tests succeed, because particularly in markets like the US where there is an appetite for expensive tests, I think they could be very useful and some of them could be very accurate. So thats always a good thing, but what were providing is a routine, easy to use, lower cost alternative.

I think there are going to be things happening at both ends of the market, both at our end and also at the more complicated end of the market. A lot of it will be based on the epigenetics and not just the DNA the complete package of the epigenetics, the nucleosomes and the whole chromosome will make a big difference.

So, there are quite a few things in development that may work and I think theres going to be a real revolution in cancer diagnostics over the next five years. People will be able to get blood tests to get diagnosed early and hopefully well be a part of that.

Read the rest here:
Q&A: discussing cancer blood testing tech with Volition - Verdict Medical Devices - Medical Device Network

Cambodian director Rithy Panh survived the brutal Khmer Rouge regime that took the lives of many of his friends and family. His latest film Irradiated, which premiered in competition at the Berlin International Film Festival, does not shy away from human horrors like those he experienced in his youth.

The film pieces together brutal black-and-white archival war footage spread across a tryptic of panels, juxtaposing footage of Hitler with the devastation of Hiroshima and a basket of decapitated heads, or executions and mass burials.

Irradiated is a difficult, visceral viewing experience an artistic choice that Panh pondered seriously, he said in a recent masterclass at the Sarajevo Film Festival moderated by Variety.

Of course theres a moral question. Why do you want to show this body? Its possible to show a body, or not to. Its a difficult [decision] in both the selection and editing process, Panh acknowledges. Why this [image] and not another one? And why at this place and not another place?

Panh reflected on the work of Claude Lanzmann, who chose not to use gruesome archival footage in his iconic documentary Shoah, and Alain Resnais, who did in Night and Fog, excerpts of which appear in Irradiated. In the end, he decided to make use of such imagery because it helped him delve deeper into his understanding of his own dark past, and the broader question of human evil.

I watched a lot of images and decided to use only those that had an echo on me, that I came to [having had] the same experience, he said.

The choice to use disturbing footage of Nazis tossing corpses from recently liberated concentration camps into a mass grave, for instance, was a difficult one. I did it myself in another context, says Panh, who was forced as a young man to bury bodies in the same fashion. Its a scene for me about why we dont respect [them] more, these bodies? If an image echoes or resonates in my mind, I assume the responsibility to edit it.

History, for Panh, thus becomes raw material for personal inquiry. He feels it justifiable to submit viewers to such a disturbing onslaught because his creative act of filmmaking is itself a defiance of such violence, and a step in the process of rebuilding himself.

Creativity is a fight against the destruction, he said.

When he started working on Irradiated, he spent nearly two years of work on the film in Japan speaking with the hibakusha the irradiated people, as Panh calls them who are the surviving victims of the atomic bombings of Hiroshima and Nagasaki.

An encounter with lab mice at an epigenetic research lab in Zurich, however, changed the entire direction of the film. Whereas normal mice will try to swim when placed in water, the descendants of traumatized mice will give up quickly, allowing themselves to drown and die, he cites. After discovering epigenetics, when I got back to the film it was a whole other thing, he said.

Cinema is important for me, says Panh. It reverts [traumatic] processes for me and teaches me how to swim. Irradiated is perhaps a way for me to understand, maybe, my own situation, and what I can do to not transmit this trauma.

When asked about a present atrocity, the ongoing incarceration and oppression of the Uighur people in Chinas northwestern region of Xinjiang, Panh, one of cinemas foremost chroniclers of genocide, did not have any comment specific to that situation.

He instead broadened his response to condemn the way digital media cuts us off from opportunities for the type of deep reflection needed to live harmoniously together and to create great cinema.

For me, its more than [just a matter of] country; the digital also censors us a lot, he said. When information moves too quickly, there is no time for reflection, leading people to be easily manipulated, he explained. Now people want immediate pictures, immediate info, [but] you need time to analyze, to watch, to step back. Its become a way to censor a diversity of points of view.

Panh, by contrast, is a fan of taking things slow.

He was supposed to start shooting a new film in March, but has grounded those plans for now while it remains impossible to travel due to COVID-19. The pandemic has given him time to stop and talk to his vegetables in the garden and notice the increase of birdsong in Paris. Hes mulling his next projects, which include a documentary on the symbolic use and commercial exchange of Cambodian statuary, and perhaps new ventures inspired by COVID on how animals come to take power in cities as they empty of human presence, or the rise of totalitarian governance tactics in response to the virus.

Cinema is on death row now, he added. Modern filmmaking is all about speed, he assesses, and the movie industry puts more money in digital platforming and less and less towards cinema as literature. One day we will all be dead from this kind of lack of reflection.

See the rest here:
Cambodias Rithy Panh Discusses the Ethical Quandaries of Irradiated at the Sarajevo Film Festival - Variety

It seems like only yesterday that Claudia Schiffer and her supermodel colleagues Cindy, Linda, Naomi and Christy ruled the runwaysin the 1990's. But in reality, it's been a good few decades since the original 'supers' reigned supreme.

Still, it's those same faces that many of usGen X'ers continue toaspire to, especially as many of them are now in their 50's- and looking better than ever - without obvious cosmetic procedures or surgery.

Claudia Schiffer turns 50 today, yetshe could easily be mistaken for someonein her 30's. Of course she does, she's got ridiculouslygood genes, I hear you scoff. Ah,but it's not as simple as allthat.

While there is no doubt that Claudia won the facial lottery, there's plenty of 'traditionally' beautiful starlets whose lookshave crumbled under the accumulationof life's many stresses - and some typically ordinary faces who have grown more youthful looking with age.

The common denominator in looking good, it seems, is lifestyle -or to be fancy about it, epigenetics: the effects thatour external lifestyle choices have on our perceived age.

Claudia's attitude to ageing is a holistic one. She believes in taking care of herface with natural organic skincare, eating healthily, exercisingandbeing out in nature. Which would explain why she's teamed up with organic lifestyle brand,Bamford, to launch an exclusive limited editionbeauty bag to celebrate her 50th birthday - a chosen edit of theactual products that Schiffer has been using on her face and body for years.

I was dying to know what's inside her limited edition collectionso that I can slap it all on in a bid to reach 50 looking half as youthful as she does, and I suspect you're curious too.

The bespoke bag designed by Carole Bamfordand Claudia contains a selection of five daily skincare and wellness essentials that are inClaudias beauty regime tocelebrates'the confidence that comes with age when you look after your health and well-being.'

Claudiasays, 'Im thrilled that in celebration of my 50th birthday Bamford have curated the products I use in my daily routine,into a limited-edition set, complete with a bespoke Claudia beauty bag. I love natural skincare and have used Bamfords products for years. They contain no harmful chemicals or preservatives, feel luxurious and are effective. Their organic and sustainable ethos is also very important to me.'

See the original post here:
As Claudia Schiffer turns 50, we reveal the skincare products she actually uses - Telegraph.co.uk

CMI published a business research report on Epigenetics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20202027. Epigenetics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.

Click To Get Free PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1772

The worldwide Epigenetics Market report stresses the most recent advancements, development, new chances, and lethargic traps. It gives a comprehensive position of the worldwide Epigenetics Market. The Epigenetics Market research report covers the present scenario and the growth prospects of the global Epigenetics Market industry for 2020-2027. The report enlists several important factors, starting from the basics to advanced market intelligence which play a crucial part in strategizing. Epigenetics Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Epigenetics Market industry.

Leading Market Player Profile Included in This Report is: Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Most of the information assembled is exhibited in a graphical frame alongside the related measurements. The Epigenetics Market report exhibits the working of the fundamental market players, providers, and merchants in detail. The report likewise features the limitations and drivers affecting the Epigenetics Market.

The report likewise incorporates a fundamental profile and data of all the significant market players at present dynamic in the worldwide Epigenetics Market. The organizations canvassed in the report can be assessed based on their most recent advancements, monetary and business diagram, item portfolio, enter drifts in the market, long haul and here and now business methodologies by the organizations with the end goal to remain aggressive in the market.

Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1772

Important Features of the Epigenetics Market:

To build up a far-reaching, verifiable, every year refreshed and financially savvy data dependent on execution, capacities, objectives, and systems of the worlds driving organizations.

To help current providers reasonably evaluate their money related, advertising and innovative capacities opposite driving contenders.

To help potential market contestants in assessing imminent acquisitions and joint endeavor hopefuls.

To supplement associations inner rival data gathering endeavors by giving vital investigation, information understanding, and knowledge.

To distinguish the slightest focused market specialties with huge development potential.

Global Epigenetics Market: Regional Segment Analysis

North America (U.S., Canada, Mexico),

Europe (Germany, U.K., France, Italy, Russia, Spain etc),

South America (Brazil, Argentina etc)

Middle East & Africa (Saudi Arabia, South Africa etc).

Asia-Pacific (China, Japan, India)

In order to get a deeper view of Market Size, competitive landscape is provided i.e. Revenue (Million USD) by Players (2015-2020), Revenue Market Share (%) by Players (2015-2020) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/1772

Available Customizations

As per specific needs customizations of the given market data is also available. Talk to our research consultant to design an exclusive report as per your research needs like Regional and country-level analysis of market by end-use, detailed analysis and profiles of additional market players.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Read more here:
Epigenetics Market 2020-2026: Global economy,Financial Share, Prominent Players,Competitive Environment,Types and Applications of Product/Service...

Ever had a bad experience with a prescription?

Ever thought it was an allergic reaction to a medication?

In 2017 I had a significant abdominal surgery that required me to take pain medication, anti-inflammatories, and antibiotics. The surgery was supposed to help with a significant abdominal umbilical hernia. It occurred on a Wednesday, and by Monday, I was having a significant reaction to the pain medication, where my FACE went NUMB. Talk about scary.

Leading up to the surgery, I had taken part in 2 appointments where I discussed previous bad reactions to the pain medication and talked about my concerns. They told me it was a necessary evil in this case so that I could sleep. The morning of surgery, after long discussion with the anesthesiologist, He asked if I had testing done to look at my response to different drugs. At that time, I didnt even know that was a thing that could be done.

The news media and medical media lately has talked a lot about epigenetics and epigenomics and we are starting to hear about pharmacogenetics. Pharmacogenetics can be done through DNA testing to specifically look at your genetics and how they might react to specific types of drugs. They can allow for better dosing, better drug choice so there is less guess work, and overall better outcomes. Pharmacogenetics can also help in looking at how some people may become addicted and others not to things like marijuana, which the Prop 64 group in Colorado would have us believe is not possible.

Pharmacogenetics can also let us know when it might be time to change a drug, because the epigenetics/epigenomics, or the environmental factors that cause the genes to change may have been affected over long-term use of specific drugs. These drugs can be related to addiction treatment, pain management, mental health disorders (bipolar, schizophrenia, depression), autoimmune logical drugs including chemotherapy.

Along the line of epigenetics/epigenomics, there is a specific testing that can be done that supports your DNA sections. It looks at what will optimally support your health, and with that information we can create a supplement that is SPECIFIC to you. Repeating the test about 6 months after initial testing and consuming of those supplements is recommended due to the changes you could potentially make. Then every year.

Why would you need a DNA-specific supplement? Colorado has one of the highest levels of radiation exposure in the continental U.S. Specifically, we have a lot of naturally occurring uranium and radon. Both of those are known carcinogens. Also, think about how much and what type of sunscreen you apply every year in Colorado while enjoying the outdoor lifestyle you love. Chemical barriers are more likely to interact with the radiation from the sun to create mutation of cells. It starts at the skin level, but quickly spreads to the body as the skin is an organ that ABSORBS things you put on it.

If you have questions about how DNA testing can improve your health, life and longevity, dont hesitate to reach out!

References:

*https://dnalife.academy/dna-health/

*Recent developments in genetic/genomic medicine, Rachel H. Horton and Anneke M. Lucassen, Clin Sci (Lond). 2019 Mar 15; 133(5): 697708.Published online 2019 Mar 5. Prepublished online 2019 Feb 27. doi: 10.1042/CS20180436

*Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry; Azmeraw T. Amare,1 Klaus Oliver Schubert,1,2 and Bernhard T. Baune1; EPMA J. 2017 Sep; 8(3): 211227.Published online 2017 Sep 5. doi: 10.1007/s13167-017-0112-8*Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants; Ramn Cacabelos,1,2,* Luca Fernndez-Novoa,1,2 Roco Martnez-Bouza,1,2 Adam McKay,1,2 Juan C. Carril,1,2 Valter Lombardi,1,2 Lola Corzo,1,2 Ivn Carrera,1,2 Ivn Tellado,1,2 Laura Nebril,1,2 Margarita Alcaraz,1,2 Susana Rodrguez,1,2 ngela Casas,1,2 Vernica Couceiro,1,2 and Antn lvarez1,2Pharmaceuticals (Basel). 2010 Oct; 3(10): 30403100.Published online 2010 Sep 29. doi: 10.3390/ph3103040*Some observations on the role of environment and genetics in behaviour of wild and domestic forms of Sus scrofa (European wild boars and domestic pigs)S Robert, J Dancosse, A Dallaire Applied Animal Behaviour Science, 1987 Elsevier

Read this article:
Genetics and Pharmacology | YourHub - The Know

VIENNA and SAN DIEGO, June 17, 2020 /PRNewswire/ -- Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowledge bases.

Lexogen's QuantSeq 3' mRNA-Seq is a straightforward, fast, and cost-efficient method for library preparation. It has been widely used for expression profiling analysis and is currently featured in more than 470 publications. "QuantSeq is a well-established library preparation kit, validated by researchers who have used it for a broad range of applications. We are continuously enhancing the workflow based on the user feedback, and offering a complete solution including data analysis has always been top priority", said Dalia Daujotyte, Chief Commercial Officer at Lexogen.

As a platform for scientists, ROSALIND empowers QuantSeq 3' customers to analyze, interpret and collaborate globally on differential gene expression analysis without the need for specialized bioinformatics or programming skills. "Through our collaborations, it is our goal to provide full transcriptome analysis solutions vetted by experts in their fields. Access to QuantSeq data processing on ROSALIND not only gives an opportunity to an in-depth gene expression analysis, but also enables collaboration and multi-omics work without leaving the environment", added Daujotyte.

"QuantSeq 3' has been a game-changer for our biotech and pharma clients adopting RNA-seq, with the compelling economics to support high volume and the ability to assess the whole transcriptome," said Tim Wesselman, CEO of OnRamp Bio. "With ROSALIND, QuantSeq users of every skill level are empowered to visually explore same day results, save valuable time and restore the thrill of discovery," added Wesselman.

The usage of ROSALIND for QuantSeq data analysis and interpretation will be demonstrated in the GenomeWeb webinar "Integration of 3'mRNA-Seq and ChIP-Seq Datasets to Disentangle Redundant Epigenetic Regulatory Mechanisms", taking place on June 18, 2020. Register here: bit.ly/2AN9URF

About Lexogen

Established in 2007, Lexogen is a transcriptomics and Next-Generation Sequencing company, focusing on the development of innovative methods for RNA analysis. Its portfolio includes multiple innovative and well-established protocols for RNA sequencing sample preparation, external RNA spike-in controls, as well as bioinformatics tools and sequencing services. Lexogen is a privately held company, headquartered in Vienna, Austria with a subsidiary in New Hampshire, US.

To learn more, visit http://www.lexogen.com and follow @lexogen.

Contact person:Jekaterina AleksejevaSenior Marketing ManagerTel.: +43 699 1023 8946Email: jekaterina.aleksejeva@lexogen.com

About OnRamp Bioinformatics

OnRamp BioInformatics is the San Diego genomics software company that develops and maintains the ROSALIND discovery and collaboration platform designed for biologists and researchers. ROSALIND is globally deployed and trusted by top pharma, biotech and research institutions as the leading cloud platform for transcriptomics and epigenetics with comprehensive QC, deep pathway interpretation, advanced multi-omic meta-analyses and collaborative gene signatures.

To learn more, visit http://www.onramp.bio and follow us on Twitter or LinkedIn (@OnRampBio).

Contact person:Cassandra ElwellInvestor Relations & Communications OfficerTel.: +1 855 766 7267 ext. 708Email: cassandra@onramp.bio

Logo - https://mma.prnewswire.com/media/472869/Lexogen_logo_Logo.jpg Logo - https://mma.prnewswire.com/media/1192411/Lexogen_Logo.jpg

HOME

SOURCE Lexogen

The rest is here:
Lexogen and OnRamp Bioinformatics partner to provide differential gene expression data analysis and interpretation for QuantSeq 3' mRNA-Seq users - PR...

WUXI, CHINA / ACCESSWIRE / June 3, 2020 / Lisen Imprinting Diagnostics Inc. ("Lisen" or "the company"), a US company headquartered with main operations in Wuxi, China which specializes on tumor epigenetics research for advancing early-stage cancer detection, announces a new epigenetic-based cancer diagnostic method. The technology which innovatively applied visualized epigenetic imprinting biomarkers has been published in the open access journal Clinical Epigenetics on May 24.

Lisen developed and patented the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology - a novel approach in identifying, visualizing, and quantifying the biallelic and multiallelic expressions of an imprinted gene panel associated with cancer status. In a 1013-case clinical study involving ten different cancer types including bladder, breast, colorectal, esophageal, gastric, lung, pancreatic, prostate, skin and thyroid cancers, QCIGISH achieved 94% overall sensitivity and 92% overall specificity.

Dr. Chunxue Bai, chief physician and professor of Zhongshan Hospital of Fudan University, one of the corresponding authors said, "Epigenetic alterations which occur prior to morphological changes are involved in most cancers, but its application in cancer diagnosis is still limited. More practical and intuitive methods to detect the aberrant expressions from clinical samples using highly sensitive biomarkers are needed."

Using the QCIGISH technology, Dr. Bai and a group of researchers from Ohio State University, Johns Hopkins University, University of Texas, Fudan University, Tongji University, Chinese Navy Medical University, Jiangsu Jiangyuan Hospital, Chinese Academy of Medical Science, evaluated the normal and aberrant expressions measured using the imprinted gene panel to formulate diagnostic models, which could accurately distinguish the imprinting differences of normal and benign cases from cancerous tissues. The new method proved effective for many different cancer types.

"We believe that QCIGISH will become a practically useful and powerful clinical tool by effectively supplementing standard cytologic and histopathologic diagnosis for early-stage cancer detection", the paper's primary author Dr. Rulong Shen, a pathologist of Ohio State University Wexner Medical Center remarked.

Dr. Ning Zhou, Lisen's CEO and co-founder, and the paper's other corresponding author added, "We have barely scratched the surface. Our current research conceptually opens a new diagnostic area in epigenetics-based cancer detection and demonstrates strong potential for high throughput clinical application. We expect that this technology may go beyond a diagnostic technique to also provide information on prognostic and predictive markers of treatment response. We are excited to discover more imprinted gene cancer biomarkers, proceed with an even larger prospective validation and extend the capabilities of our technology to foster hope to cancer patients around the world."

About Cancer Early Detection and Epigenetics

The incidence of cancer is 18.1 million and the mortality is 9.6 million every year (GLOBOCAN 2018). The survival rate of cancer patients decreases dramatically from early to advanced stages. Therefore, early cancer detection plays a vital role in improving patients' long-term survival. However, this remains a huge clinical challenge due to the absence of sufficient morphological evidences to enable a definitive diagnosis. Epigenetic changes such as DNA methylation, histone methylation and acetylation, and expression status of imprinting genes which all occur at precancerous stages and promote carcinogenesis, could serve as sensitive biomarkers for early cancer detection.

About Lisen Imprinting Diagnostics, Inc.

Lisen Imprinting Diagnostics, Inc. is a US company registered in Delaware dedicated to the accurate and early identification of cancers at their most curable stages. By developing advanced cancer detection technology, Lisen hopes to provide a personalized pathway for patients towards effective therapies while avoiding unnecessary, costly and potentially futile treatment. Collaborating with various medical centers from Shanghai, Nanjing, Dalian, Hangzhou, Zhengzhou and Wuxi, China, Lisen has studied 6500+ clinical cases involving 12 different cancer types. The company holds 20 Chinese and international intellectual properties on early cancer detection.

For further information, contact:

Ning Zhou | 001-8016990666| zhou.ning@lisenid.comLisen, CEOLisen Imprinting Diagnostics Inc.66 Jinghui East Boulevard #5601Wuxi, Jiangsu 214135China

SOURCE: Lisen Imprinting Diagnostics Inc.

View source version on accesswire.com: https://www.accesswire.com/592713/Lisen-Imprinting-Diagnostics-Inc-Announces-a-New-Innovative-and-Highly-Accurate-Epigenetic-Solution-for-Early-Cancer-Detection

Continued here:
Lisen Imprinting Diagnostics Inc. Announces a New Innovative and Highly Accurate Epigenetic Solution for Early Cancer Detection - Benzinga

OXFORD, England--(BUSINESS WIRE)--Epigenetics company Base Genomics has launched with a team of leading scientists and clinicians to set a new gold standard in DNA methylation detection. The company has closed an oversubscribed seed funding round of $11 million USD (9 million GBP) to progress development of its TAPS technology, initially focusing on developing a blood test for early-stage cancer and minimal residual disease. The funding round was led by Oxford Sciences Innovation and also included investors with industry expertise in genomics and oncology.

DNA methylation is an epigenetic mechanism involved in gene regulation and has been shown to be one of the most promising biomarkers for detecting cancer through liquid biopsy. The existing industry standard for mapping DNA methylation degrades DNA and reduces sequence complexity, however, limiting scientific discovery and clinical sensitivity. Base Genomics new technology, TAPS, overcomes these issues and generates significantly more information from a given sample, creating new opportunities in research and the clinic.

"In order to realize the potential of liquid biopsies for clinically meaningful diagnosis and monitoring, sensitive detection and precise quantification of circulating tumour DNA is paramount, said Base Genomics CMO Anna Schuh. Current approaches are not fit for purpose to achieve this, but Base Genomics has developed a game-changing technology which has the potential to make the sensitivity of liquid biopsies a problem of the past."

First developed at Ludwig Institute for Cancer Research Branch at the University of Oxford, TAPS is a novel chemical reaction that converts methylated cytosine to thymine under mild conditions. Unlike the industry standard technology, bisulfite sequencing, TAPS does not degrade DNA, meaning that significantly more DNA is available for sequencing. TAPS also better retains sequence complexity, cutting sequencing costs in half and enabling simultaneous epigenetic and genetic analysis.

Genomic technologies with the power, simplicity and broad applicability of TAPS come along very infrequently, said Base Genomics CTO Vincent Smith. It has the potential to have an impact on epigenetics similar to that which Illumina's SBS chemistry had on Next Generation Sequencing.

Base Genomics is led by a highly experienced team of scientists and clinicians, including Dr Vincent Smith, a world-leader in genomic product development and former Illumina VP; Dr Anna Schuh, Head of Molecular Diagnostics at the University of Oxford and Principal Investigator on over 30 clinical trials; Drs Chunxiao Song and Yibin Liu, co-inventors of TAPS at the Ludwig Institute for Cancer Research, Oxford; and Oliver Waterhouse, previously an Entrepreneur in Residence at Oxford Sciences Innovation and founding team member at Zinc VC.

The ability to sequence a large amount of high-quality epigenetic information from a simple blood test could unlock a new era of preventative medicine, said Base Genomics founder and CEO Oliver Waterhouse. In the future, individuals will not just be sequenced once to determine their largely static genetic code, but will be sequenced repeatedly over time to track dynamic epigenetic changes caused by age, lifestyle, and disease.

Visit link:
Base Genomics Announces Company Launch and Raises $11 Million USD to Commercialize Epigenetic Technology for Early and Sensitive Detection of Cancer...

Professor Reik is an internationally renowned expert in the field of epigenetics and has led the Institutes Epigenetics research programme since 2008. He has been the Institutes Associate Director since 2004.

Professor Peter Rigby, FRS, Chair of the Institutes Board of Trustees, said: I am delighted to announce that the Institute Board has appointed Professor Wolf Reik FRS as the Acting Director of the Babraham Institute. Professor Reik is a world-class scientist, internationally renowned for his work in epigenetics, who has been at the Institute for over 30 years. The BBSRC fully support the Board's appointment, which will ensure the Institute continues to be strongly led, building on the excellent work of Professor Michael Wakelam. I know that Wolf will provide much needed leadership and stability during the uncertain times that we all face.

Professor Reik commented: I am really honoured by this appointment; I look forward to working with everyone at the Institute, the Campus and with BBSRC. After Michaels sad death, my primary aim is to bring us back to our labs in a safe and considerate fashion, and to jointly tackle the opportunities and challenges for the science of the Institute going forward strongly into the future.

Professor Reiks research centres on understanding the role of epigenetics (non-sequence altering modifications to DNA or chromatin that regulate gene expression) in establishing cell fate and identity during mammalian development and also the process of epigenetic reprogramming. The research interests of his lab span understanding the epigenetic processes governing the earliest steps of development, how pluripotency is maintained in stem cells and conversely how cell identity is established during differentiation. More recently the lab is interested in how the epigenome degrades during ageing, and whether there are ways of reversing this decay. They have developed new technologies for single cell multi-omics sequencing which allows unprecedented insights into cell fate changes during development or ageing. Professor Reik enjoys collaborating with scientists in the Institute and outside, and leads a Wellcome-funded consortium that studies cell fate decisions during mouse gastrulation and organ development.

Professor Reik is honorary Professor of Epigenetics and Affiliate Faculty at the Stem Cell Institute at the University of Cambridge and Associate Faculty at the Wellcome Sanger Institute. He is a member of EMBO and the Academia Europaea (elected in 2003 and 2011, respectively), and a Fellow of the Academy of Medical Sciences (2003) and of the Royal Society (2010). Professor Reik has been a member of funding committees of several of the UKs key research funders such as UKRI-Medical Research Council, Cancer Research UK and Wellcome Trust.

Professor Reik obtained his MD from the University of Hamburg in 1985. He undertook his thesis work with Rudolf Jaenisch in Hamburg, followed by postdoctoral work with Azim Surani at the Institute of Animal Physiology, now the Babraham Institute. During this time, he became a Fellow of the Lister Institute of Preventive Medicine which provided funding to start his own independent research group (in 1987).

Image: Professor Wolf Reik. Courtesy of Keith Heppell and the Cambridge Independent.

Read the rest here:
Professor Wolf Reik FRS appointed Acting Director of the Babraham Institute - Cambridge Network